Drug Type Synthetic peptide |
Synonyms- |
Target |
Mechanism CECR2 inhibitors(CECR2 histone acetyl-lysine reader inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic breast cancer | Preclinical | CN | 01 Jul 2024 |